Monday, December 5, 2022

Comments by tbehrendt

Showing 5 of 5 comments.

  • Jeffrey Lieberman is one of the nation’s leading proponents of outpatient commitment and forced “treatment” laws. He was a major booster of the draconian Murphy bill. In testimony before Congress and in interviews, speeches and presentations to psychiatrists and to the public, Lieberman has impugned critics of psychiatry, often connecting them with the Church of Scientology.

    I want to be informed about how powerful institutions like the APA and bullies like Lieberman (recipients of vast sums from Pharma) throw their weight around and successfully wield their influence with the New York Times and other media. (Given that drug ads are a top revenue driver for the media, maybe we shouldn’t be surprised about the ease with which Lieberman gets it to do his bidding.)
    Thank you for the article.

  • “Although commentators bravely assert that ‘advances in neurobiological research methods allow one to address the nature and biological basis of human behavior’ [and] that jurors can be counted on to critically evaluate such evidence…. the visual allure [of neuroimaging evidence] dazzle and seduce jurors in ways that are “inappropriately persuasive.” Perlin, Michael & Rae McClain, Valerie. (2010). Unasked (and Unanswered) Questions About the Role of Neuroimaging in the Criminal Trial Process. American Journal of Forensic Psychology. 28.

  • From Dr. Lieberman’s Wikipedia entry:
    “In 2006, Lieberman co-signed a letter to the editor of The Wall Street Journal with about thirty other doctors. With this, he disclosed honoraria, consulting fees, research grant support from AstraZeneca, Bristol-Myers Squibb, Upjohn Pharmacia, Novartis, Eli Lilly, Janssen, Pfizer, Hoechst AG, and AstraZeneca. He also listed as corporate speakers bureaus AstraZeneca, Janssen, Eli Lilly, and Pfizer. Lieberman disclosed in 2007 in the journal Primary Psychiatry that he was a consultant to Eli Lilly and Pfizer. He was on the advisory boards of AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, and Pfizer. He has a patent from Repligen Corporation. Lieberman received research support from Acadia, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck, Organon, and Pfizer. In 2009, Lieberman disclosed grants from Allon, Forest Laboratories, Merck, Pfizer, AstraZeneca, Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Janssen, Otsuka, Solvay, and Wyeth to the American College of Neuropsychopharmacology for their annual meeting in which he participated. In 2011, his disclosure at Medscape of relevant financial relationships says he served on the advisory board of Bioline, GlaxoSmithKline, Intra-Cellular Therapies, Eli Lilly, Pierre Fabre, and Psychogenics, and that he received research grants from Allon Therapeutics, GlaxoSmithKline, Ortho-McNeil-Janssen, Merck, Novartis, Pfizer, Sepracor, and Targacept. He also disclosed in 2013, as a member of the psychiatry editorial board at Medscape, that he received research grants from Allon, Novartis, Sepracor, and Targacept; and he served on the advisory boards at Bioline, Intra-Cellular Therapies, Pierre Fabre and Psychogenics. In additional disclosures at Medscape in 2013, he received research grants from Allon, GlaxoSmithKline, Eli Lilly, Merck, Novartis, Pfizer, Psychogenics, Hoffmann-La Roche, Sepracor, and Targacept, and he served on the advisory board of Alkermes, Bioline, Intra-Cellular Therapies, Pierre Fabre, and Psychogenics.”
    “A note on ‘competing interests’ for contributors to the book Essentials of Schizophrenia (2011) says Lieberman receives no direct financial compensation for his research, consulting and advisory board activities (except Intra-Cellular Therapies.”